Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1992-01

AUTHORS

Thomas Reissmann, Peter Hilgard, Johannes H. Harleman, Jürgen Engel, Ana M. Comaru-Schally, Andrew W. Schally

ABSTRACT

Cetrorelix, (Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10)-LHRH (SB-75) is a new highly potent antagonist of LH-RH. In the model of DMBA-induced mammary carcinoma, this antagonist was very effective in reducing tumor mass. A rapid decrease in tumor weights to levels below 0.1 g total tumor mass was achieved with 300 micrograms/kg given sc. daily for 14 days. The weights of uteri and ovaries were reduced to about 40-50% of control values. In all treated rats the estrus cycle was interrupted and the animals remained in a state of anestrus. Microscopically, the effects of Cetrorelix on the tumors were characterized by a loss of mitotic activity, marked regression with apoptosis, an increase of stroma and differentiation towards a normal mammary architecture. On the basis of a dose-response curve, a dose of 100 micrograms/kg/d of Cetrorelix was determined as sufficient for a full antitumor response. Large DMBA-tumors with total tumor mass of about 6 g could also be treated very effectively with a dose of 100 micrograms/kg/d. To achieve a complete tumor regression, the treatment had to last 34 days. After the cessation of treatment with 100 micrograms/kg/d and regrowth of the tumors the animals were treated with the agonist Decapeptyl (Trp6-LHRH) using a dose of 50 micrograms/rat/d for 14 days. Again, the tumors responded well and regressed within 10 days. The treatment with an overlapping dose schedule of Cetrorelix and Decapeptyl showed a continuous antitumor response. A transient stimulation of tumor growth by the LH-RH agonist was not observed under these experimental conditions. In ovariectomized rats bearing DMBA-tumors, treatment with Cetrorelix and estradiol, produced no tumor growth inhibition as compared to estradiol control group, indicating that there is no estrogen nullifying effect of this antagonist on tumor cells in this model. On the basis of these results, Cetrorelix is a highly effective antitumor agent in this breast cancer model, which might also be useful under clinical conditions. More... »

PAGES

44-49

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01192310

DOI

http://dx.doi.org/10.1007/bf01192310

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014519714

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1530849


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "9,10-Dimethyl-1,2-benzanthracene", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation, Preclinical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gonadotropin-Releasing Hormone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mammary Neoplasms, Experimental", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Inbred Strains", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triptorelin Pamoate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reissmann", 
        "givenName": "Thomas", 
        "id": "sg:person.01340535776.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340535776.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hilgard", 
        "givenName": "Peter", 
        "id": "sg:person.01023655171.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023655171.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harleman", 
        "givenName": "Johannes H.", 
        "id": "sg:person.01356310665.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356310665.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Engel", 
        "givenName": "J\u00fcrgen", 
        "id": "sg:person.011670303512.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011670303512.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tulane University", 
          "id": "https://www.grid.ac/institutes/grid.265219.b", 
          "name": [
            "V. A. Medical Center and Tulane School of Medicine, New Orleans, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Comaru-Schally", 
        "givenName": "Ana M.", 
        "id": "sg:person.01256576041.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256576041.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tulane University", 
          "id": "https://www.grid.ac/institutes/grid.265219.b", 
          "name": [
            "V. A. Medical Center and Tulane School of Medicine, New Orleans, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schally", 
        "givenName": "Andrew W.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0010-7824(82)90096-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001699959"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.85.5.1637", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002795752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0015-0282(16)47899-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002957219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198311243092104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006895646"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1399-3011.1988.tb01373.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013430231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1399-3011.1988.tb01373.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013430231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0010-7824(84)80008-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014057857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0015-0282(16)38580-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015549193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/189204a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025224664", 
          "https://doi.org/10.1038/189204a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1963.59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031239879", 
          "https://doi.org/10.1038/bjc.1963.59"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1963.59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031239879", 
          "https://doi.org/10.1038/bjc.1963.59"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0305-7372(89)90008-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032038868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0024-3205(85)90462-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040748313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0024-3205(85)90462-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040748313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.80.5.1459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043379393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.86.5.1648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043920489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0015-0282(16)53330-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046317199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0028-1111993", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057127511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/82.6.513", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059816349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/endo-124-2-946", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064262154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079671890", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082525481", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1992-01", 
    "datePublishedReg": "1992-01-01", 
    "description": "Cetrorelix, (Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10)-LHRH (SB-75) is a new highly potent antagonist of LH-RH. In the model of DMBA-induced mammary carcinoma, this antagonist was very effective in reducing tumor mass. A rapid decrease in tumor weights to levels below 0.1 g total tumor mass was achieved with 300 micrograms/kg given sc. daily for 14 days. The weights of uteri and ovaries were reduced to about 40-50% of control values. In all treated rats the estrus cycle was interrupted and the animals remained in a state of anestrus. Microscopically, the effects of Cetrorelix on the tumors were characterized by a loss of mitotic activity, marked regression with apoptosis, an increase of stroma and differentiation towards a normal mammary architecture. On the basis of a dose-response curve, a dose of 100 micrograms/kg/d of Cetrorelix was determined as sufficient for a full antitumor response. Large DMBA-tumors with total tumor mass of about 6 g could also be treated very effectively with a dose of 100 micrograms/kg/d. To achieve a complete tumor regression, the treatment had to last 34 days. After the cessation of treatment with 100 micrograms/kg/d and regrowth of the tumors the animals were treated with the agonist Decapeptyl (Trp6-LHRH) using a dose of 50 micrograms/rat/d for 14 days. Again, the tumors responded well and regressed within 10 days. The treatment with an overlapping dose schedule of Cetrorelix and Decapeptyl showed a continuous antitumor response. A transient stimulation of tumor growth by the LH-RH agonist was not observed under these experimental conditions. In ovariectomized rats bearing DMBA-tumors, treatment with Cetrorelix and estradiol, produced no tumor growth inhibition as compared to estradiol control group, indicating that there is no estrogen nullifying effect of this antagonist on tumor cells in this model. On the basis of these results, Cetrorelix is a highly effective antitumor agent in this breast cancer model, which might also be useful under clinical conditions.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf01192310", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "118"
      }
    ], 
    "name": "Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone", 
    "pagination": "44-49", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "452bc5e672883777d6ab4f5334c573c2f76091f150a5067b54fea8d11087dd13"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1530849"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7902060"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01192310"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014519714"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01192310", 
      "https://app.dimensions.ai/details/publication/pub.1014519714"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000370_0000000370/records_46775_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF01192310"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01192310'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01192310'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01192310'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01192310'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      21 PREDICATES      61 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01192310 schema:about N03a6bcd0fb52435c80e240d84dfce93f
2 N21948139b41747c78af040c03a43d952
3 N22bd9450f2124a40b31b02dc33289581
4 N3600bafb678d42a48fa9698cb9b5a7c6
5 N45eb01ead4c244b3be37ab539c7eed5d
6 N544eb1ff658947daaa56ed2cbe63a9af
7 N75ae1affb7644e43904e727744b2d449
8 N84dfc709e6cf46438280888843ad5dbd
9 N892f554f19204c2db36b8fe62a5dfff9
10 Naf0638a21040436f869057b0fa1eed15
11 Nbf28dfdaa60044fe97c9321b1ebdc3bb
12 Nce23a0f08d4a4d7e80800d3352211e7b
13 Ne0fbc6c43b4c42aa9b5f189b2dfef7aa
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author Nef29584a428a497d9098366cbb4e17be
17 schema:citation sg:pub.10.1038/189204a0
18 sg:pub.10.1038/bjc.1963.59
19 https://app.dimensions.ai/details/publication/pub.1079671890
20 https://app.dimensions.ai/details/publication/pub.1082525481
21 https://doi.org/10.1016/0010-7824(82)90096-8
22 https://doi.org/10.1016/0024-3205(85)90462-x
23 https://doi.org/10.1016/0305-7372(89)90008-x
24 https://doi.org/10.1016/s0010-7824(84)80008-6
25 https://doi.org/10.1016/s0015-0282(16)38580-6
26 https://doi.org/10.1016/s0015-0282(16)47899-4
27 https://doi.org/10.1016/s0015-0282(16)53330-5
28 https://doi.org/10.1055/s-0028-1111993
29 https://doi.org/10.1056/nejm198311243092104
30 https://doi.org/10.1073/pnas.80.5.1459
31 https://doi.org/10.1073/pnas.85.5.1637
32 https://doi.org/10.1073/pnas.86.5.1648
33 https://doi.org/10.1093/jnci/82.6.513
34 https://doi.org/10.1111/j.1399-3011.1988.tb01373.x
35 https://doi.org/10.1210/endo-124-2-946
36 schema:datePublished 1992-01
37 schema:datePublishedReg 1992-01-01
38 schema:description Cetrorelix, (Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10)-LHRH (SB-75) is a new highly potent antagonist of LH-RH. In the model of DMBA-induced mammary carcinoma, this antagonist was very effective in reducing tumor mass. A rapid decrease in tumor weights to levels below 0.1 g total tumor mass was achieved with 300 micrograms/kg given sc. daily for 14 days. The weights of uteri and ovaries were reduced to about 40-50% of control values. In all treated rats the estrus cycle was interrupted and the animals remained in a state of anestrus. Microscopically, the effects of Cetrorelix on the tumors were characterized by a loss of mitotic activity, marked regression with apoptosis, an increase of stroma and differentiation towards a normal mammary architecture. On the basis of a dose-response curve, a dose of 100 micrograms/kg/d of Cetrorelix was determined as sufficient for a full antitumor response. Large DMBA-tumors with total tumor mass of about 6 g could also be treated very effectively with a dose of 100 micrograms/kg/d. To achieve a complete tumor regression, the treatment had to last 34 days. After the cessation of treatment with 100 micrograms/kg/d and regrowth of the tumors the animals were treated with the agonist Decapeptyl (Trp6-LHRH) using a dose of 50 micrograms/rat/d for 14 days. Again, the tumors responded well and regressed within 10 days. The treatment with an overlapping dose schedule of Cetrorelix and Decapeptyl showed a continuous antitumor response. A transient stimulation of tumor growth by the LH-RH agonist was not observed under these experimental conditions. In ovariectomized rats bearing DMBA-tumors, treatment with Cetrorelix and estradiol, produced no tumor growth inhibition as compared to estradiol control group, indicating that there is no estrogen nullifying effect of this antagonist on tumor cells in this model. On the basis of these results, Cetrorelix is a highly effective antitumor agent in this breast cancer model, which might also be useful under clinical conditions.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree false
42 schema:isPartOf N4bbd3bd74a9b4435a58f7041d81dabfe
43 N6587483acd6148dfba3e4aba2d536596
44 sg:journal.1313647
45 schema:name Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone
46 schema:pagination 44-49
47 schema:productId N59be164795274cfd8e04f8e281702802
48 Na35441e2fe69407db2303de995cb4987
49 Naca6ac59ad0244d18ff71f58cb519f47
50 Ncb8831283a6a48999972c30ae8c67155
51 Nf39f364e162f4dd2896adb08632035d4
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014519714
53 https://doi.org/10.1007/bf01192310
54 schema:sdDatePublished 2019-04-11T13:35
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N71d5a1b951d84c3d857b006dd13be1dc
57 schema:url http://link.springer.com/10.1007/BF01192310
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N03a6bcd0fb52435c80e240d84dfce93f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Cell Survival
63 rdf:type schema:DefinedTerm
64 N0df7ada0e3a24ff2940bbb37117c18b3 rdf:first sg:person.01023655171.21
65 rdf:rest N7ca29036c91f4812b60dfb46478aaf13
66 N21948139b41747c78af040c03a43d952 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Dose-Response Relationship, Drug
68 rdf:type schema:DefinedTerm
69 N21c2b27fad314de587de09bdc73e616c rdf:first N2f4704a133d54f5aa3eb344b67486554
70 rdf:rest rdf:nil
71 N22bd9450f2124a40b31b02dc33289581 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Rats
73 rdf:type schema:DefinedTerm
74 N2a1352e5e4ba4997a6391efdef7cf669 schema:name Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany
75 rdf:type schema:Organization
76 N2f4704a133d54f5aa3eb344b67486554 schema:affiliation https://www.grid.ac/institutes/grid.265219.b
77 schema:familyName Schally
78 schema:givenName Andrew W.
79 rdf:type schema:Person
80 N3600bafb678d42a48fa9698cb9b5a7c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Rats, Inbred Strains
82 rdf:type schema:DefinedTerm
83 N420fb2f5b9cc4aa8bfbd61f833d46137 schema:name Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany
84 rdf:type schema:Organization
85 N45eb01ead4c244b3be37ab539c7eed5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name 9,10-Dimethyl-1,2-benzanthracene
87 rdf:type schema:DefinedTerm
88 N4bbd3bd74a9b4435a58f7041d81dabfe schema:volumeNumber 118
89 rdf:type schema:PublicationVolume
90 N544eb1ff658947daaa56ed2cbe63a9af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Gonadotropin-Releasing Hormone
92 rdf:type schema:DefinedTerm
93 N59be164795274cfd8e04f8e281702802 schema:name pubmed_id
94 schema:value 1530849
95 rdf:type schema:PropertyValue
96 N6587483acd6148dfba3e4aba2d536596 schema:issueNumber 1
97 rdf:type schema:PublicationIssue
98 N71d5a1b951d84c3d857b006dd13be1dc schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 N75ae1affb7644e43904e727744b2d449 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Antineoplastic Agents
102 rdf:type schema:DefinedTerm
103 N7ca29036c91f4812b60dfb46478aaf13 rdf:first sg:person.01356310665.28
104 rdf:rest Ncdb29a914308495897e2b61af7f1d189
105 N84dfc709e6cf46438280888843ad5dbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Triptorelin Pamoate
107 rdf:type schema:DefinedTerm
108 N892f554f19204c2db36b8fe62a5dfff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Mammary Neoplasms, Experimental
110 rdf:type schema:DefinedTerm
111 Na35441e2fe69407db2303de995cb4987 schema:name doi
112 schema:value 10.1007/bf01192310
113 rdf:type schema:PropertyValue
114 Naca6ac59ad0244d18ff71f58cb519f47 schema:name nlm_unique_id
115 schema:value 7902060
116 rdf:type schema:PropertyValue
117 Naf0638a21040436f869057b0fa1eed15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Antineoplastic Combined Chemotherapy Protocols
119 rdf:type schema:DefinedTerm
120 Nbf28dfdaa60044fe97c9321b1ebdc3bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Female
122 rdf:type schema:DefinedTerm
123 Ncb8831283a6a48999972c30ae8c67155 schema:name dimensions_id
124 schema:value pub.1014519714
125 rdf:type schema:PropertyValue
126 Ncdb29a914308495897e2b61af7f1d189 rdf:first sg:person.011670303512.58
127 rdf:rest Nd7bf1d4088ac470691f660cee4e5dc33
128 Nce23a0f08d4a4d7e80800d3352211e7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Drug Evaluation, Preclinical
130 rdf:type schema:DefinedTerm
131 Nd2413f6aab7943eb930a76ac5f6da978 schema:name Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany
132 rdf:type schema:Organization
133 Nd3446a173cf347dc8963f90b708acd0f schema:name Department of Clinical Cancer Research, ASTA Pharma AG, P.O. Box 100105, W-6000, Frankfurt 1, Federal Republic of Germany
134 rdf:type schema:Organization
135 Nd7bf1d4088ac470691f660cee4e5dc33 rdf:first sg:person.01256576041.88
136 rdf:rest N21c2b27fad314de587de09bdc73e616c
137 Ne0fbc6c43b4c42aa9b5f189b2dfef7aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Animals
139 rdf:type schema:DefinedTerm
140 Nef29584a428a497d9098366cbb4e17be rdf:first sg:person.01340535776.53
141 rdf:rest N0df7ada0e3a24ff2940bbb37117c18b3
142 Nf39f364e162f4dd2896adb08632035d4 schema:name readcube_id
143 schema:value 452bc5e672883777d6ab4f5334c573c2f76091f150a5067b54fea8d11087dd13
144 rdf:type schema:PropertyValue
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
149 schema:name Clinical Sciences
150 rdf:type schema:DefinedTerm
151 sg:journal.1313647 schema:issn 0171-5216
152 1432-1335
153 schema:name Journal of Cancer Research and Clinical Oncology
154 rdf:type schema:Periodical
155 sg:person.01023655171.21 schema:affiliation Nd2413f6aab7943eb930a76ac5f6da978
156 schema:familyName Hilgard
157 schema:givenName Peter
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023655171.21
159 rdf:type schema:Person
160 sg:person.011670303512.58 schema:affiliation Nd3446a173cf347dc8963f90b708acd0f
161 schema:familyName Engel
162 schema:givenName Jürgen
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011670303512.58
164 rdf:type schema:Person
165 sg:person.01256576041.88 schema:affiliation https://www.grid.ac/institutes/grid.265219.b
166 schema:familyName Comaru-Schally
167 schema:givenName Ana M.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256576041.88
169 rdf:type schema:Person
170 sg:person.01340535776.53 schema:affiliation N2a1352e5e4ba4997a6391efdef7cf669
171 schema:familyName Reissmann
172 schema:givenName Thomas
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340535776.53
174 rdf:type schema:Person
175 sg:person.01356310665.28 schema:affiliation N420fb2f5b9cc4aa8bfbd61f833d46137
176 schema:familyName Harleman
177 schema:givenName Johannes H.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356310665.28
179 rdf:type schema:Person
180 sg:pub.10.1038/189204a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025224664
181 https://doi.org/10.1038/189204a0
182 rdf:type schema:CreativeWork
183 sg:pub.10.1038/bjc.1963.59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031239879
184 https://doi.org/10.1038/bjc.1963.59
185 rdf:type schema:CreativeWork
186 https://app.dimensions.ai/details/publication/pub.1079671890 schema:CreativeWork
187 https://app.dimensions.ai/details/publication/pub.1082525481 schema:CreativeWork
188 https://doi.org/10.1016/0010-7824(82)90096-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001699959
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1016/0024-3205(85)90462-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040748313
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1016/0305-7372(89)90008-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1032038868
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1016/s0010-7824(84)80008-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014057857
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1016/s0015-0282(16)38580-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015549193
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/s0015-0282(16)47899-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002957219
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/s0015-0282(16)53330-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046317199
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1055/s-0028-1111993 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057127511
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1056/nejm198311243092104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006895646
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1073/pnas.80.5.1459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043379393
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1073/pnas.85.5.1637 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002795752
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1073/pnas.86.5.1648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043920489
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1093/jnci/82.6.513 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059816349
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1111/j.1399-3011.1988.tb01373.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1013430231
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1210/endo-124-2-946 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064262154
217 rdf:type schema:CreativeWork
218 https://www.grid.ac/institutes/grid.265219.b schema:alternateName Tulane University
219 schema:name V. A. Medical Center and Tulane School of Medicine, New Orleans, USA
220 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...